Hormone Health · Evidence Guide

Hormone Health: What the Evidence Actually Supports

Menopause and perimenopause, BHRT, testosterone and TRT, peptides — a physician-led map of what the evidence supports and what’s just marketing.

The 30-second answer

Evidence-based: FDA-approved menopausal hormone therapy started near menopause; transdermal estradiol with micronized progesterone; testosterone for men with confirmed, symptomatic hypogonadism plus monitoring.

Promising, needs nuance: low-dose testosterone for women for specific indications; the “New Menopause” movement’s core message, refined for the individual.

Overhyped: routine compounded “custom” BHRT; pellets marketed as superior; saliva hormone mapping.

What we won’t do: prescribe TRT without a real workup, or sell compounded BHRT as inherently safer than FDA-approved options.

Hormone content is everywhere right now — “meno TikTok,” testosterone influencers, compounded pellet clinics, peptide stacks. Some reflects solid endocrinology; a lot is marketing dressed up as medicine. This guide is our map of the field: what the evidence supports, where it needs nuance, and what we decline to offer. Where the research is genuinely mixed, we say so.

How we grade the trends

Solid — consistently supported by high-quality trials or major guidelines.
Mixed — a real signal, but limited, early, or modest evidence.
Weak — little reliable human evidence; claims outrun the data.
Pseudoscience — contradicted by evidence, or built on unvalidated tests.

The hormone conversations, at a glance

Each links to a full, sourced deep-dive. This table is the hub — add a row whenever you publish another article in the cluster.

Article	Our read
FDA removes the HRT black-box warning	After 23 years, the FDA lifted the warning in 2026. What changed, and what it doesn’t change.
Compounded vs. FDA-approved hormones	ACOG/NAMS/NASEM caution against routine compounded BHRT — occasionally the right call. Weak.
The “New Menopause” playbook	What Mary Claire Haver gets right, and where individual care refines it. Mixed.
Perimenopause symptoms no one warned you about	It’s not just hot flashes — the signs that show up years early.
BHRT delivery: pellets, patches, creams, pills	Transdermal is well-supported; pellets are oversold as superior. Mixed.
Estrogen, brain health & the Alzheimer’s window	What the “window” hypothesis does — and doesn’t — say, minus the hype. Mixed.
Testosterone for women	What it actually treats, what it doesn’t, and the careful approach. Mixed.
How low is “Low T”, really?	The number matters less than symptoms plus a confirmed workup (AUA). Solid method, hyped labels.
The TRAVERSE trial & TRT heart safety	5,246 men, the clearest answer yet on cardiovascular risk. Solid.
TRT & fertility, before your first injection	Testosterone can affect fertility — the steps to take first.
What TikTok won’t tell you about TRT	What algorithm-driven testosterone content leaves out. Mixed.
Cypionate shortage 2026	Why your refill got weird, and what your options are.
Peptides, explained: GLP-1, BPC-157, GH	GLP-1s solid; BPC-157 in regulatory limbo; GH secretagogues need monitoring. Mixed to weak.
The midlife hormone reset (for couples)	When both partners shift at once, the fix starts at one shared lab visit.

Three patterns worth spotting

1. “Optimization” as a moving target. A normal-range value gets relabeled a deficiency to justify treatment. A testosterone of 380 can be fine for one person and worth treating in another — symptoms and a full workup decide, not a single number.

2. “Bioidentical” framed as “safer.” Compounded hormones are sold as more natural and therefore safer. FDA-approved bioidentical options exist, are tested for dose and consistency, and are what the major bodies recommend first.

3. Delivery-method hype. Pellets get marketed as superior; the evidence generally favors transdermal estradiol and micronized progesterone. The best delivery method is the one chosen with the patient, not sold to them.

Ready to get evaluated?

Hormone care at Naya starts with labs and a real conversation — never a template. Explore the services this guide connects to:

Bioidentical Hormone Replacement (BHRT) — menopause, perimenopause, estrogen & progesterone therapy.
Testosterone Replacement Therapy (TRT) — diagnosis, options, and monitoring for men.
Peptide Therapy — evidence-based peptides, honestly scoped.
Thyroid Health — the companion evidence guide.

Book a consultation →

Hormone Health FAQ

Is hormone therapy safe after the WHI scare?

For many women, yes. The original WHI headlines were substantially reappraised, and in 2026 the FDA removed HRT’s long-standing black-box warning. For healthy women starting near menopause, the benefit-risk balance is generally favorable — but it depends on your age, time since menopause, and history.

Are compounded “bioidentical” hormones safer than FDA-approved ones?

Not inherently. ACOG, The Menopause Society, and NASEM recommend FDA-approved options first because they’re tested for dose and consistency. Compounding is legal and occasionally the right call, but “compounded” is not a synonym for “safer.”

Do I need testosterone if my level is “low-normal”?

Maybe not. A single low-normal number isn’t a diagnosis. Guidelines call for confirmed, repeated low readings plus genuine symptoms before starting testosterone — and then ongoing monitoring.

Does Naya offer hormone services?

Yes — BHRT, TRT, peptide therapy, and thyroid optimization, all clinician-supervised with lab-based diagnosis and monitoring.

Sources

The 2022 Hormone Therapy Position Statement of The Menopause Society (NAMS).
Mulhall et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018.
ACOG Committee Opinion: Compounded Bioidentical Menopausal Hormone Therapy.
NASEM. The Clinical Utility of Compounded Bioidentical Hormone Therapy. 2020.
Lincoff et al. Testosterone and Cardiovascular Outcomes (TRAVERSE). NEJM 2023.

Educational content, not medical advice. Speak with a qualified clinician before starting or stopping any medication or treatment. Naya Wellness · Chatsworth & Santa Barbara, California.